DAFTAR PUSTAKA

1. *Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.* **Rhodes A, Jasani B, Balaton AJ et al.** 2000, J. Clin. Pathol, hal. 53, 688–696.

2. *Treatment of primary breast cancer with chemotherapy and tamoxifen.* **Fisher B, Redmond C, Brown A et al.** 1981, N. Engl. J. Med, hal. 305, 1–6.

3. *Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.* **Fisher B, Redmond C, Brown A et al.** 1983, J. Clin. Oncol, hal. 1, 227–241.

4. *Estrogen-receptor interactions in target tissue.* **Jensen EV, Desombre ER, Hurst DJ et al.** 1967, Arch. Anat. Microsc. Morphol, hal. 547–569.

5. *Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups.* **Chu KC, Anderson WF.** 2002, Breast Cancer Res. Treat, hal. 74, 199–211.

6. *Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.* **Dunnwald LK, Rossing MA, Li CI.** 2007, Breast Cancer Res. 9, R6.

7. *Ethnicity and breast cancer: factors influencing differences in incidence and outcome.* **Chlebowski RT, Chen Z, Anderson GL et al.** 2005, J. Natl Cancer Inst., hal. 97, 439–448.

8. *Factors affecting estrogen receptor status in a multiracial Asian country: an analysis of 3557 cases.* **Yip CH, Pathy NB, Uiterwaal CS et al.** 2011, Breast 20(Suppl.), hal. S60–S64.

9. *Risk factors for breast cancer according to estrogen and progesterone receptor status.* **Colditz GA, Rosner BA, Chen WY et al.** 2004, J. Natl Cancer Inst., hal. 96, 218–228.

10. *Identification of breast cancer recurrence risk factors based on functional pathways in tumor and normal tissues Impact.* **ChenX, LiuL,WangY,LiuB,ZengD,JinQ,et al.** 2017, Journal Oncotarget., hal. 8(13):20679–94.

11. *The recurrence frequency of breast cancer and its prognostic factors in Iranian* **Shahriari-Ahmadi A, Arabi M, Payandeh M, Sadeghi M.** 2017, International plied and Basic Medical Research, hal. 7(1):40.

ostic factors. stage and receptor status in breast cancer. **donegan.** 1992, l. 70:1755–64.

13. *Update breast cancer management diagnostic and treatment. Majalah Kedokteran Andalas.* **M, Ramli.** 2015, Majalah Kedokteran Andalas, hal. 38(Suppl.1):28-53.

14. **Khan, Ibrahim O. Alanazi and Zahid.** Endocrine and Cell Surface Receptor Signaling in Breast carcinogenesis. [pengar. buku] nilufer bulut. *breast cancer and surgery.* 2018.

15. **Mahdi Rezai, Mehmet Ali Kocdor Nuh Zafer Canturk.** *Breast Cancer Essentials, Perspectives for Surgeons.* turkey : springer, 2021.

16. **F. Charles Brunicardi, Dana, Timothy, David, John, Jeffrey, Raphael.** *Schwartz's Principles of Surgery.* new york : mc graw hill , medical, 2015.

17. **COURTNEY, BEAUCHAMP, EVERS, MATTOX.** *SABISTON TEXTBOOK of SURGERY The BIOLOGICAL BASIS of MODERN SURGICAL PRACTICE.* MISSOURI : elsevier, 2022.

18. *Estimates of worldwide burden of cancer in 2008.* **Ferlay J, Shin HR, Bray F et al.** 2010, GLOBOCAN 2008, hal. int. J. Cancer 127, 2893–2917.

19. *AJCC Cancer Staging Atlas Second Edition. Springer Science+Business Media, .* **Compton, Carolyn C., Byrd, David R., Garcia-Aguilar, Julio., Kurtzman, Scott H., Olawaiye, Alexander., and Washington, Mary Kay.** 2012, hal. LLC , 32 : 419-440.

20. *Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients .* **Nan Yao, Zhenchuan Song, Xinle Wang, Shan Yang, Heng Song.** s.l. : J Breast Cancer , 2017, Vol. 20(2): 160-169.

21. *New Insights in Estrogen Receptor (ER) Biology and Implications for Treatment.* **Aabha Oza, Cynthia X.** new york : Springer Science+Business Media , 2017.

22. *Estrogen Receptor–Positive, Progesterone Receptor– Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance.* **Grazia Arpino, Heidi Weiss, Adrian V. Lee, Rachel Schiff, Sabino De Placido, C. Kent Osborne, Richard M. Elledge.** s.l. : Journal of the National Cancer Institute, 2005, Vol. 95.

23. *Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors.* **Cherry Bansal, Aarti Sharma, Mukta Pujani, Meenu Pujani, Kiran Lata Sharma, Srivastava, Singh;.** india : Wolters Kluwer - Medknow, 2017, Indian Journal of Medical and Paediatric Oncology, Vol. 38.

24. *The seed and soil hypothesis revisited - the role of tumor-stroma interactions in*
s to different organs. **Fidler, Robert R. Langley and Isaiah J.** houston : danderson.org., 2011, Int J Cancer, Vol. 128. doi:10.1002/ijc.26031..

nical course of bone metastases from breast cancer. **Rubens, .E. Coleman &**
ıe Macmillan Press Ltd, 1987, Br. J. Cancer, Vol. 55.

26. *Retrospective analysis of metastatic behaviour of breast cancer subtypes.* **C. Dilara Savci-Heijink1 • Hans Halfwerk, Gerrit K. J. Hooijer, Hugo M. Horlings, Jelle Wesseling, Marc J. van de Vijver1.** s.l. : springerlink.com, 2015, Breast Cancer Res Treat. DOI 10.1007/s10549-015-3352-0.

27. *Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer.* **Ananya Pareek, O. P. Singh, Veenita Yogi, H. U. Ghori, Vivek Tiwari, Pallavi Redhu.** india : Wolters Kluwer - Medknow, 2017.